HORIZON EUROPE
Europeo
Specific Challenge:Personalised medicine uses data generated by new technologies to better understand the individual characteristics in order to deliver the right care to the right person at the right time. This approach has substantial potential for tackling major health challenges, such as cancer and rare diseases, helping to deliver better and more effective health outcomes. In order to seize this potential, there is a need to support the large scale pooling of expertise and of genomic and other health data, as well as to identify common standards for the generation, analysis and sharing of this data.
Coordination and support is needed to develop cross-border solutions for sharing expertise and linking genomic and other health data. This should be achieved by identifying relevant initiatives and projects, discerning best practice emerging from clinical implementation and engaging with relevant stakeholders. It is critical to identify common standards for data quality, security, interoperability, privacy, ethical guidelines and governance models underpinning the establishment of sustainable cross-border digital infrastructures and networks for genomics and personali...
ver más
Specific Challenge:Personalised medicine uses data generated by new technologies to better understand the individual characteristics in order to deliver the right care to the right person at the right time. This approach has substantial potential for tackling major health challenges, such as cancer and rare diseases, helping to deliver better and more effective health outcomes. In order to seize this potential, there is a need to support the large scale pooling of expertise and of genomic and other health data, as well as to identify common standards for the generation, analysis and sharing of this data.
Coordination and support is needed to develop cross-border solutions for sharing expertise and linking genomic and other health data. This should be achieved by identifying relevant initiatives and projects, discerning best practice emerging from clinical implementation and engaging with relevant stakeholders. It is critical to identify common standards for data quality, security, interoperability, privacy, ethical guidelines and governance models underpinning the establishment of sustainable cross-border digital infrastructures and networks for genomics and personalised medicine in Europe.
Scope:This action should aim to support the identification of common standards, cross-border digital infrastructures and coordination mechanisms to advance personalised medicine in Europe. It should build on existing initiatives, projects and resources at national, regional and European level.
This CSA should consolidate knowledge from existing initiatives and projects to identify the most appropriate practices, standards and governance models for establishing cross-border digital infrastructures supporting genomics research and personalised medicine in Europe.
In a coordinated effort with national initiatives, Research & Innovation projects, and other stakeholders (among them national authorities, health institutions, standardisation bodies, ICT industry), the action should develop coordination mechanisms for sharing expertise and for securely linking genomic and other health data (eg electronic health records, registries, including rare disease registries etc), respecting legal (including but not limited to similarities and differences in EU Member states and associated countries, standardisation, type approval etc.) and ethics requirements. This CSA should identify and facilitate the exchange of best practices between relevant R&I projects, initiatives and other stakeholders. It should provide an overview of relevant standards for data quality, security, interoperability, privacy and ethics. It should identify critical elements of a system of transparent governance of a digital infrastructure enabling the cross-border linking of genomic and other health data in Europe. It should also develop a quality risk management concept for sustainability and further development.
For grants awarded under this topic, beneficiaries may provide support to third parties as described in General Annex K of the Work Programme either in form of grants or prizes. The respective options of Article 15 of the Model Grant Agreement will be applied.
The Commission considers that proposals requesting from the EU up to EUR 4 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected Impact:The proposal should provide appropriate indicators to measure its progress and specific impact in the following areas:
Agreed standards and mechanisms for the cross-border linking and analysis of genomic and other health data with potential for wide-spread adoption across Europe.Adequate basis for developing a cross-border digital infrastructure for linking genomic and other health data in Europe.Best possible and secure use of genomic and other health data for personalized medicine.Adequate basis for investment decisions in personalized medicine (both private and public) based on expected returns.Support Europe’s global leadership in personalized medicine.
Cross-cutting Priorities:Open InnovationOpen Science
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Coordination and Support Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
6. Additional provisions:
Horizon 2020 budget flexibility
Classified informatio... 1. Eligible countries: described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Coordination and Support Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply
For grants awarded under this topic [for [insert name(s) of type(s) of action beneficiaries may provide support to third parties as described in part K of the General Annexes of the Work Programme either in form of grants or prizes. The respective options of Article 15 of the Model Grant Agreement will be applied.
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
8. Additional documents:
1. Introduction WP 2018-2020
2. Health, demographic change and well-being WP 2018-20
18. Dissemination, Exploitation and Evaluation WP 2018-20
20. Cross-cutting activities WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta